Researchers test supercharged TB drug dose in major safety trial
NCT ID NCT06057519
Summary
This study is testing if a much higher daily dose of the tuberculosis drug rifampicin is safe and works better than the standard dose. It will involve 164 adults with lung TB, checking for liver damage and other side effects while seeing if patients recover faster. The goal is to find a more effective treatment regimen to control TB.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, PULMONARY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ASL Città di Torino
RECRUITINGTurin, Italy
-
Radboud University Medical Centre
RECRUITINGNijmegen, Netherlands
Contact
Conditions
Explore the condition pages connected to this study.